AI drug discovery company launched in 2024 with $1B in committed funding, fusing ML and wet-lab biology
Biotech📍 South San Francisco, CAFounded 2023
Current Valuation
$1.0B
as of 2024-Q2
UNICORN
IPO Outlookprivate
Is Xaira Therapeutics going public?
No. Xaira Therapeutics has no imminent IPO plans on record. It is still private.
What is Xaira Therapeutics' valuation in 2026?
Xaira Therapeutics is valued at $1.0B as of 2024-Q2, set by its Series A ($1.0B, Apr 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Xaira Therapeutics filed an S-1?
No public S-1 is on file for Xaira Therapeutics.
Who are Xaira Therapeutics' investors?
Xaira Therapeutics' investors include ARCH Venture Partners, Foresite Labs, F-Prime Capital, NEA, Sequoia, Lightspeed and 2 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Xaira Therapeutics launched in April 2024 with $1 billion in committed funding — among the largest biotech Series A rounds ever — incubated by ARCH Venture Partners and Foresite Labs. CEO Marc Tessier-Lavigne is the former president of Stanford University and former CSO of Genentech. The platform builds on RFdiffusion and protein-design discoveries from David Baker's lab at the University of Washington (where Baker won the 2024 Nobel Prize in Chemistry). Targeting oncology and immunology indications.
Company Profile
CEO
Marc Tessier-Lavigne
Founded
2023
HQ
South San Francisco, CA
Employees
~150
Total Raised
$1.0B
Growth
Pre-revenue / pre-clinical
Last Round
Series A — $1.0B (Apr 2024) · Lead: ARCH Venture Partners + Foresite Labs (co-leads)
IPO Status
no imminent plans
Fundraising Status
Series A · $1.0B · 2y 4mo ago
no imminent plansTotal raised $1.0B
Secondary Market
Implied price / share
$4.39
Open interest
2
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series A
$1.0B
Apr 2024
ARCH Venture Partners + Foresite Labs (co-leads)
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Xaira Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-08-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
36% of roles posted in last 30d
Open roles
22
via greenhouse
Product-build share
68%
engineering, research, product, design
Trajectory
steady
heavy product build — 68% of open roles are product-building functions (engineering/research/product) — 12 of 22 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
AI Research EngineerAI Scientist, BioMedical AIAI Scientist - Biomedical Multimodal ModelingAI Scientist, Computational Protein DesignAssociate Director, Analytical Development (Biologics)Associate Scientist, Phage Display (Contract)
Counted from Xaira Therapeutics's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Marc Tessier-LavigneRobert PlengeJohn Maraganore
Investors
ARCH Venture Partners · Foresite Labs · F-Prime Capital · NEA · Sequoia · Lightspeed · Two Sigma Ventures · Ravelin Capital
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q2. Refreshed quarterly.